中文摘要：

目的初步探讨肝癌肝移植受者术后CD4＋CD25＋T淋巴细胞在移植排斥反应中的作用。方法应用流式细胞术检测肝癌肝移植受者25例和肝硬化肝移植受者3（）例术后外周血中CD4＋CD25＋T淋巴细胞的比例，并以正常志愿者的血液样本作为对照，进行比较分析。另设动物实验，实验组（n=8）将小鼠肝癌细胞H22种植到C57BL／6小鼠肝脏，再将Balb／c小鼠的皮肤移植到患有肝癌的C57BL／6小鼠背部；对照组（n=7）将Balb／c皮肤移植到正常的C57BL／6小鼠的背部，观察两组小鼠移植皮肤的存活时间。结果肝癌肝移植受者外周血CD4＋CD25＋T淋巴细胞在CD4＋T淋巴细胞中的比例为（10．00±1．15）％，高于肝硬化肝移植者的（5．10＋1．50）％（P〈O．05）。实验组小鼠移植皮肤的存活时间为（14．25±1．94）d，长于对照组的（8．86±1．35）d（P％0．05）。结论肝癌肝移植受者术后外周血中CD4＋CD25＋T淋巴细胞的比例增高；增高的CD4＋CD25＋T淋巴细胞可能与肝癌肝移植术后排斥反应的发生延迟相关。

英文摘要：

Objective To discuss the significance of CD4＋ CD25＋ regulatory T （Treg） cells in the hepatocellular carcinoma （HCC） patients after liver transplantation. Method The frequency of Treg ceils in the HCC patients was analyzed hy flow cytometry, and compared with that in patients with liver cirrhosis （LC） and normal people. A mouse HCC model was established by injection of mice hepatic cancer cell H22 to the C57BL/6 liver. Skin transplantation was performed on the normal mice （n = 7, control group） and the HCC mice （n = 8, experimental group）, and the skin graft survival time was observed. Result The frequency of Treg cells in the peripheral blood （PB） of HCC patients after liver transplantation was （10. 00 ± 1.15）%, and （5. 10 ± 1.50）% in LC group,P〈0. 05. The skin graft survival time in experimental group （14. 25 ±1.94 days） was longer than in control group （8. 86 ± 1.35 days, P〈0. 05）. Conclusion Increased Treg cells can delay or reduce the rate of allograft rejection; moreover it suggests that we can use the immunosuppressants more reasonably in the HCC patients after liver transplantation via detecting the Treg cells.